{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:40:46Z","timestamp":1790671246868,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19 AI084024"],"award-info":[{"award-number":["U19 AI084024"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI119164"],"award-info":[{"award-number":["R01 AI119164"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.vaccine.2017.01.023","type":"journal-article","created":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T04:02:22Z","timestamp":1484884942000},"page":"7289-7294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Status of vaccine research and development of vaccines for Chlamydia trachomatis infection"],"prefix":"10.1016","volume":"37","author":[{"given":"Taylor B.","family":"Poston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami L.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Darville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.01.023_b0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1745-6215-9-73","article-title":"Community-based trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial","volume":"9","author":"Oakeshott","year":"2008","journal-title":"Trials"},{"key":"10.1016\/j.vaccine.2017.01.023_b0010","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0197-2456(98)00022-1","article-title":"Design of the PID Evaluation and Clinical Health (PEACH) study","volume":"19","author":"Ness","year":"1998","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.vaccine.2017.01.023_b0015","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00007435-199207000-00001","article-title":"Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results","volume":"19","author":"Westrom","year":"1992","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2017.01.023_b0020","doi-asserted-by":"crossref","first-page":"e0146663","DOI":"10.1371\/journal.pone.0146663","article-title":"Chlamydia trachomatis infection of endocervical epithelial cells enhances early HIV transmission events","volume":"11","author":"Buckner","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.01.023_b0025","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/01.olq.0000154504.54686.d1","article-title":"Metaanalysis and metaregression in interpreting study variability in the impact of sexually transmitted diseases on susceptibility to HIV infection","volume":"32","author":"Sexton","year":"2005","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2017.01.023_b0030","doi-asserted-by":"crossref","first-page":"e0143304","DOI":"10.1371\/journal.pone.0143304","article-title":"Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting","volume":"10","author":"Newman","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.01.023_b0035","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1001\/jama.291.18.2229","article-title":"Prevalence of chlamydial and gonococcal infections among young adults in the United States","volume":"291","author":"Miller","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2017.01.023_b0040","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"386","author":"Global Burden of Disease Study C","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.01.023_b0045","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/OLQ.0b013e318285c6d2","article-title":"The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008","volume":"40","author":"Owusu-Edusei","year":"2013","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2017.01.023_b0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/sextrans-2014-051531","article-title":"Feasibility of Chlamydia trachomatis screening and treatment in pregnant women in Lima, Peru: a prospective study in two large urban hospitals","volume":"91","author":"Cabeza","year":"2015","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2017.01.023_b0055","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1258\/ijsa.2010.010093","article-title":"Chlamydia screening in non-clinical settings","volume":"21","author":"Durber","year":"2010","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.vaccine.2017.01.023_b0060","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1097\/OLQ.0b013e31818b64ac","article-title":"The program cost and cost-effectiveness of screening men for Chlamydia to prevent pelvic inflammatory disease in women","volume":"35","author":"Gift","year":"2008","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2017.01.023_b0065","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/sti.2006.024364","article-title":"The cost effectiveness of opportunistic chlamydia screening in England","volume":"83","author":"Adams","year":"2007","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2017.01.023_b0070","doi-asserted-by":"crossref","first-page":"c1642","DOI":"10.1136\/bmj.c1642","article-title":"Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial","volume":"340","author":"Oakeshott","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2017.01.023_b0075","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.amepre.2010.05.011","article-title":"Uptake of regular chlamydia testing by U.S. women: a longitudinal study","volume":"39","author":"Heijne","year":"2010","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.vaccine.2017.01.023_b0080","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/sti.2010.048694","article-title":"What is the cost of pelvic inflammatory disease and how much could be prevented by screening for Chlamydia trachomatis? Cost analysis of the Prevention of Pelvic Infection (POPI) trial","volume":"87","author":"Aghaizu","year":"2011","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2017.01.023_b0085","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/OLQ.0b013e31823e2ff7","article-title":"Chlamydia trachomatis trends in the United States among persons 14 to 39 years of age, 1999\u20132008","volume":"39","author":"Datta","year":"2012","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2017.01.023_b0090","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/OLQ.0b013e31827bd637","article-title":"Screening and treating Chlamydia trachomatis genital infection to prevent pelvic inflammatory disease: interpretation of findings from randomized controlled trials","volume":"40","author":"Gottlieb","year":"2013","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2017.01.023_b0095","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1086\/648734","article-title":"Repeated Chlamydia trachomatis genital infections in adolescent women","volume":"201","author":"Batteiger","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.01.023_b0100","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/OLQ.0b013e31815e41a3","article-title":"The arrested immunity hypothesis and the epidemiology of chlamydia control","volume":"35","author":"Brunham","year":"2008","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2017.01.023_b0105","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/S0140-6736(07)60367-5","article-title":"Global perspectives on the sexual and reproductive health of adolescents: patterns, prevention, and potential","volume":"369","author":"Bearinger","year":"2007","journal-title":"Lancet"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2017.01.023_b0110","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1086\/652399","article-title":"Protective immunity to chlamydial genital infection: evidence from animal studies","volume":"201","author":"Rank","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.01.023_b0115","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00007435-199401000-00010","article-title":"Age and clinical immunity to infections with Chlamydia trachomatis","volume":"21","author":"Arno","year":"1994","journal-title":"Sex Transm Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2017.01.023_b0120","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1086\/652400","article-title":"Protective immunity to Chlamydia trachomatis genital infection: evidence from human studies","volume":"201","author":"Batteiger","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.01.023_b0125","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1093\/infdis\/jit094","article-title":"Spontaneous resolution of genital Chlamydia trachomatis infection in women and protection from reinfection","volume":"207","author":"Geisler","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.01.023_b0130","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00007435-197804000-00011","article-title":"The potential for vaccine against infection of the genital tract with Chlamydia trachomatis","volume":"5","author":"Grayston","year":"1978","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2017.01.023_b0135","first-page":"699","article-title":"Trachoma vaccine field trials in The Gambia","volume":"67","author":"Sowa","year":"1969","journal-title":"J Hyg (Lond)"},{"key":"10.1016\/j.vaccine.2017.01.023_b0140","first-page":"67","article-title":"Experiments with trachoma vaccines: therapeutic effect on established trachoma","volume":"1","author":"Collier","year":"1963","journal-title":"Orient Archs Ophthal"},{"key":"10.1016\/j.vaccine.2017.01.023_b0145","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3181\/00379727-112-28112","article-title":"Field studies of protection from infection by experimental trachoma virus vaccine in preschool-aged children on Taiwan","volume":"112","author":"Grayston","year":"1963","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.vaccine.2017.01.023_b0150","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/0002-9394(67)94157-8","article-title":"Field trial of two bivalent trachoma vaccines in children of Punjab Indian villages","volume":"63","author":"Dhir","year":"1967","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.vaccine.2017.01.023_b0155","series-title":"Trachoma: prevention and treatment","author":"Bietti","year":"1967"},{"key":"10.1016\/j.vaccine.2017.01.023_b0160","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/0002-9394(67)94159-1","article-title":"Long-term follow-up of the initial (1959\u20131960) trachoma vaccine field trial on Taiwan","volume":"63","author":"Woolridge","year":"1967","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.vaccine.2017.01.023_b0165","unstructured":"Grayston J, Kim K, Alexander E, Wang S. Protective studies in monkeys with trivalent and monovalent trachoma vaccines. Trachoma and related disorders caused by Chlamydial Agents Amsterdam and New York: Excerpta Medica. 1971: 377\u201385."},{"key":"10.1016\/j.vaccine.2017.01.023_b0170","doi-asserted-by":"crossref","first-page":"791847","DOI":"10.1155\/2015\/791847","article-title":"Trachoma and ocular chlamydial infection in the era of genomics","volume":"2015","author":"Derrick","year":"2015","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.vaccine.2017.01.023_b0175","series-title":"Proceedings of the thirteenth international symposium on human chlamydial infections. Asilomar conference grounds, Pacific Grove, Calif, USA","first-page":"485","article-title":"Trachoma vaccine trials in the Gambia","author":"Bailey","year":"2014"},{"key":"10.1016\/j.vaccine.2017.01.023_b0180","series-title":"Proceedings of the thirteenth international symposium on human chlamydial infections. Asilomar conference grounds, Pacific Grove, Calif, USA","first-page":"489","article-title":"Towards a safe and effective chlamydial vaccine: lessons from the eye","author":"Hu","year":"2014"},{"key":"10.1016\/j.vaccine.2017.01.023_b0185","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1084\/jem.20111266","article-title":"A live-attenuated chlamydial vaccine protects against trachoma in nonhuman primates","volume":"208","author":"Kari","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2017.01.023_b0190","doi-asserted-by":"crossref","first-page":"aaa8205","DOI":"10.1126\/science.aaa8205","article-title":"A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells","volume":"348","author":"Stary","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.01.023_b0195","doi-asserted-by":"crossref","first-page":"902","DOI":"10.7326\/M14-1981","article-title":"Screening for chlamydia and gonorrhea: US Preventive Services Task Force recommendation statement","volume":"161","author":"LeFevre","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2017.01.023_b0200","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1016\/j.vaccine.2014.12.002","article-title":"Human papillomavirus vaccines: WHO position paper, October 2014-recommendations","volume":"33","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.01.023_b0205","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1086\/598983","article-title":"Modeling the impact of potential vaccines on epidemics of sexually transmitted Chlamydia trachomatis infection","volume":"199","author":"Gray","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.01.023_b0210","unstructured":"Rutstein SO, Shah IH. Infecundity infertility and childlessness in developing countries; 2004."},{"key":"10.1016\/j.vaccine.2017.01.023_b0215","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.fertnstert.2005.10.028","article-title":"Comparison of assisted reproductive technology utilization and outcomes between Caucasian and African American patients in an equal-access-to-care setting","volume":"85","author":"Feinberg","year":"2006","journal-title":"Fertil Steril"},{"key":"10.1016\/j.vaccine.2017.01.023_b0220","unstructured":"Centers for Disease Control and Prevention. 2013 Assisted reproductive technology, fertility clinic success rates report; 2015."},{"key":"10.1016\/j.vaccine.2017.01.023_b0225","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0140-6736(85)90594-X","article-title":"Worldwide patterns of infertility: is Africa different?","volume":"2","author":"Cates","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.01.023_b0230","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1258\/td.2011.100410","article-title":"Results of infertility investigations and follow-up among 312 infertile women and their partners in Kigali, Rwanda","volume":"41","author":"Dhont","year":"2011","journal-title":"Trop Doct"},{"key":"10.1016\/j.vaccine.2017.01.023_b0235","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1034\/j.1600-0412.2003.00175.x","article-title":"Ectopic pregnancy in African developing countries","volume":"82","author":"Goyaux","year":"2003","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.vaccine.2017.01.023_b0240","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1128\/IAI.48.3.847-849.1985","article-title":"Chronic chlamydial genital infection in congenitally athymic nude mice","volume":"48","author":"Rank","year":"1985","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.01.023_b0245","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1146\/annurev.immunol.15.1.749","article-title":"Cellular responses to interferon-gamma","volume":"15","author":"Boehm","year":"1997","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2017.01.023_b0250","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1128\/IAI.62.9.3705-3711.1994","article-title":"Tryptophan depletion as a mechanism of gamma interferon-mediated chlamydial persistence","volume":"62","author":"Beatty","year":"1994","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.01.023_b0255","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.4049\/jimmunol.180.5.3375","article-title":"Antigen-specific CD4+ T cells produce sufficient IFN-gamma to mediate robust protective immunity against genital Chlamydia muridarum infection","volume":"180","author":"Li","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.01.023_b0260","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.4049\/jimmunol.1002952","article-title":"Immunization with live and dead Chlamydia muridarum induces different levels of protective immunity in a murine genital tract model: correlation with MHC class II peptide presentation and multifunctional Th1 cells","volume":"186","author":"Yu","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.01.023_b0265","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1126\/science.1257530","article-title":"T cell memory. A local macrophage chemokine network sustains protective tissue-resident memory CD4 T cells","volume":"346","author":"Iijima","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.01.023_b0270","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1128\/IAI.59.4.1346-1351.1991","article-title":"Susceptibility to reinfection after a primary chlamydial genital infection is associated with a decrease of antigen-specific T cells in the genital tract","volume":"59","author":"Igietseme","year":"1991","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.01.023_b0275","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1128\/IAI.73.2.671-678.2005","article-title":"Antibody-mediated immunomodulation: a strategy to improve host responses against microbial antigens","volume":"73","author":"Brady","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.01.023_b0280","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/infdis\/jiv137","article-title":"Protection against Chlamydia trachomatis infection and upper genital tract pathological changes by vaccine-promoted neutralizing antibodies directed to the VD4 of the major outer membrane protein","volume":"212","author":"Olsen","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.01.023_b0285","article-title":"Chlamydia trachomatis: protective adaptive responses and prospects for a vaccine","author":"Poston","year":"2016","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2017.01.023_b0290","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13567-015-0241-9","article-title":"A review of the human vs. porcine female genital tract and associated immune system in the perspective of using minipigs as a model of human genital Chlamydia infection","volume":"46","author":"Lorenzen","year":"2015","journal-title":"Vet Res"},{"key":"10.1016\/j.vaccine.2017.01.023_b0295","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3389\/fimmu.2015.00628","article-title":"Intramuscular priming and intranasal boosting induce strong genital immunity through secretory IgA in minipigs infected with Chlamydia trachomatis","volume":"6","author":"Lorenzen","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2017.01.023_b0300","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/ni.1688","article-title":"Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans","volume":"10","author":"Querec","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2017.01.023_b0305","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1148\/radiology.210.1.r99ja04209","article-title":"MR imaging in pelvic inflammatory disease: comparison with laparoscopy and US","volume":"210","author":"Tukeva","year":"1999","journal-title":"Radiology"},{"key":"10.1016\/j.vaccine.2017.01.023_b0310","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/infdis\/jiv438","article-title":"Analysis of factors driving incident and ascending infection and the role of serum antibody in Chlamydia trachomatis genital tract infection","volume":"213","author":"Russell","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.01.023_b0315","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/01.olq.0000154508.26532.6a","article-title":"Comparison of acute and subclinical pelvic inflammatory disease","volume":"32","author":"Wiesenfeld","year":"2005","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2017.01.023_b0320","doi-asserted-by":"crossref","DOI":"10.1136\/sextrans-2013-051184.0086","article-title":"O01. 4 Blood transcriptional profiling of women with Chlamydia trachomatis identifies a Pelvic Inflammatory Disease (PID) signature","volume":"89","author":"Darville","year":"2013","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2017.01.023_b0325","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiw485","article-title":"Identification of Chlamydia trachomatis antigens recognized by T cells from highly exposed women who limit or resist genital tract infection","author":"Russell","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.01.023_b0330","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/icb.2015.79","article-title":"A multi-subunit Chlamydia vaccine inducing neutralizing antibodies and strong IFN-gamma(+) CMI responses protects against a genital infection in minipigs","volume":"94","author":"Boje","year":"2016","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2017.01.023_b0335","unstructured":"NanoBio Corporation. Nanobio's chlamydia vaccine improves clearance of bacteria, prevents pelvic inflammatory disease in mice; 2015."},{"key":"10.1016\/j.vaccine.2017.01.023_b0340","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.vaccine.2015.02.055","article-title":"Outer membrane proteins preferentially load MHC class II peptides: implications for a Chlamydia trachomatis T cell vaccine","volume":"33","author":"Karunakaran","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.01.023_b0345","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1128\/CVI.00247-15","article-title":"Resolution of Chlamydia trachomatis infection is associated with a distinct T cell response profile","volume":"22","author":"Picard","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.01.023_b0350","doi-asserted-by":"crossref","first-page":"9969","DOI":"10.1073\/pnas.1101756108","article-title":"Approach to discover T- and B-cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccines","volume":"108","author":"Finco","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.01.023_b0355","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1016\/j.vaccine.2009.04.006","article-title":"Protection of live bacteria from bile acid toxicity using bile acid adsorbing resins","volume":"27","author":"Edwards","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.01.023_b0360","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1128\/IAI.73.4.2005-2011.2005","article-title":"Antibiotic-free plasmid stabilization by operator-repressor titration for vaccine delivery by using live Salmonella enterica Serovar typhimurium","volume":"73","author":"Garmory","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.01.023_b0365","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.4049\/jimmunol.1400120","article-title":"CD8+ T cells define an unexpected role in live-attenuated vaccine protective immunity against Chlamydia trachomatis infection in Macaques","volume":"192","author":"Olivares-Zavaleta","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.01.023_b0370","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.4049\/jimmunol.179.6.4027","article-title":"Plasmid-deficient Chlamydia muridarum fail to induce immune pathology and protect against oviduct disease","volume":"179","author":"O'Connell","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.01.023_b0375","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1128\/IAI.00841-15","article-title":"Comparable genital tract infection, pathology, and immunity in rhesus macaques inoculated with wild-type or plasmid-deficient Chlamydia trachomatis serovar D","volume":"83","author":"Qu","year":"2015","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.01.023_b0380","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.vaccine.2013.10.016","article-title":"Towards a safe and effective chlamydial vaccine: lessons from the eye","volume":"32","author":"Mabey","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.01.023_b0385","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.vaccine.2013.08.032","article-title":"Current barriers, challenges and opportunities for the development of effective STI vaccines: point of view of vaccine producers, biotech companies and funding agencies","volume":"32","author":"Dodet","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.01.023_b0390","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.vaccine.2014.01.053","article-title":"Vaccines against sexually transmitted infections: the way forward","volume":"32","author":"Broutet","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.01.023_b0395","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.vaccine.2016.03.111","article-title":"The global roadmap for advancing development of vaccines against sexually transmitted infections: update and next steps","volume":"34","author":"Gottlieb","year":"2016","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17300427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17300427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T06:35:59Z","timestamp":1601361359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17300427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":79,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0264410X17300427"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.01.023","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Status of vaccine research and development of vaccines for Chlamydia trachomatis infection","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.01.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}